KDM1A overexpression
|
AML
|
KDM1A overexpression
|
AML
|
LSD1 inhibitor + ruxolitinib Sensitive: D – Preclinical
|
LSD1 inhibitor + ruxolitinib Sensitive: D – Preclinical
|
KDM1A overexpression
|
Osteosarcoma
|
KDM1A overexpression
|
Osteosarcoma
|
SP2577 Sensitive: D – Preclinical
|
SP2577 Sensitive: D – Preclinical
|
KDM1A overexpression
|
Rhabdomyosarcoma
|
KDM1A overexpression
|
Rhabdomyosarcoma
|
SP2577 Sensitive: D – Preclinical
|
SP2577 Sensitive: D – Preclinical
|
KDM1A overexpression
|
Ewing Sarcoma
|
KDM1A overexpression
|
Ewing Sarcoma
|
SP2577 Sensitive: D – Preclinical
|
SP2577 Sensitive: D – Preclinical
|